Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

Rheumatology

Volumn 48, Issue 12, 2009, Pages 1557-1559

  Quartuccio, Luca ^a   Fabris, Martina ^a   Salvin, Sara ^a   Atzeni, Fabiola ^b   Saracco, Marta ^c   Benucci, Maurizio ^d   Cimmino, Marco ^e   Morassi, Pia ^f   Masolini, Paola ^a   Pellerito, Raffaele ^c   Cutolo, Maurizio ^e   Sarzi Puttini, Piercarlo ^b   De Vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f Azienda Ospedaliera Ospedali Riuniti   (Italy)

Author keywords

Anti CCP; Anti TNF; DMARDs; Rheumatoid arthritis; Rheumatoid factor; Rituximab

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ACCURACY; ADULT; ARTICLE; DISABILITY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PEPTIDES, CYCLIC; PROGNOSIS; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 75649121049     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep314     Document Type: Article

References (21)

1. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008;47:495-9.
2. Cohen SB, Emery P, Greenwald MW et al.; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54: 2793-806.
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al.; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
4. Tak PP, Cohen SB, Emery P et al. Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, anti-CCP). Ann Rheum Dis 2007;66(Suppl. II):338.
5. Finckh A, Ciurea A, Brulhart L et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
6. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002;46:2029-33.
7. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008;58:1566-75.
8. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917-25.
9. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis. The effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008;58:3657-64.
10. Launois R, Payet S, Saidenberg-Kermanac'h N, Francesconi C, França LR, Boissier MC. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Join Bone Spine 2008;75:688-95.
11. Dörner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003;15:246-52.
12. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
13. Roll P, Palanichamy A, Rouziere AS, Dörner T, Kneitz C, Tony HP. B-cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: transient recirculation of plasma blasts and increased level of germinal center founder cell. Arthritis Rheum 2005;52(Suppl. 9):S289.
14. Leandro MJ, Cambridge G, Eherenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
15. Rouziere AS, Kneitz C, Palanichamy A, Dörner T, Tony HP. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 2005;7:R714-24.
16. Szodoray P, Alex P, Dandapani V et al. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis. Scand J Immunol 2004;60:209-18.
17. Quartuccio L, Salvin S, Fabris M, Sacco S, De Vita S. Disappearance of bone marrow B-cell clonal expansion in patients with type II HCV-related cryoglobulinemic glomerulonephritis after clinical efficient rituximab therapy. Ann Rheum Dis 2008;67: 1494-5.
18. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004;30: 393-403.
19. Carson DA, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest 1991; 87:379-83.
20. Vittecoq O, Lequerre' T, Goëb V, Le Loët X, Abdesselam TA, Klemmer N. Smoking and inflammatory diseases. Best Pract Res Clin Rheumatol 2008;22: 923-35.
21. La DT, Collins CE, Yang HT, Migone TS, Stohl W. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumor necrosis factor alpha antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis 2008;67:1132-8.